This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutNimenrix Dosing and AdministrationNimenrix in the Green BookNimenrix TravelSupport & ResourcesSupport & ResourcesClinic Support MaterialsVideosMaterials

Click here for Nimenrix® (meningococcal groups A, C, W-135 and Y conjugate vaccine) Prescribing Information.
Adverse event reporting information can be found at the bottom of the page.

Nimenrix for TravelNimenrix (meningococcal groups A, C, W-135 and Y conjugate vaccine) is for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.1When people travelling are at risk of meningococcal ACWY disease, help protect them with Nimenrix.1,2Meningococcal ACWY vaccination is a requirement for Hajj and Umrah pilgrims3All people aged 1 year and over travelling to the Kingdom of Saudi Arabia for Hajj or Umrah (including seasonal workers) require proof of meningococcal ACWY vaccination for entry.3 It is recommended to review the latest guidance before travelling. In 2017 over 25,000 British nationals performed Hajj and around 100,000 the pilgrimage of Umrah.4Meningococcal ACWY vaccination is recommended for some people travelling to the ‘meningitis belt’ of sub-Saharan Africa.2Outbreaks of meningococcal meningitis in the meningitis belt can reach epidemic proportions during the dry season (December to June).2Meningococcal ACWY vaccination may also be recommended for long-stay travellers likely to have close contact with the local population, such as2:
  • Backpackers
  • People visiting friends and relatives
  • Aid or health workers
Countries in Africa where vaccination against meningococcal disease is recommended for some travellers:5
Scroll left to view table
Countries
Benin Ethiopia Nigeria
Burkino Faso The Gambia Rwanda
Burundi Ghana Senegal
Cameroon Guinea South Sudan
Central Africa Republic Guinea Bissau Sudan
Chad Kenya Tanzania
Côte d’Ivoire (Ivory Coast) Mali Togo
Democratic Republic of Congo Mauritania Uganda
Eritrea Niger  
Why choose Nimenrix for meningococcal ACWY vaccination?
  • Nimenrix can be used to help protect a broad age range of people
    • The only meningococcal conjugate ACWY vaccine approved for use from 6 weeks of age, with no upper age limit.*1​​​​​​​
  • The first and only ACWY meningococcal conjugate vaccine with antibody persistence evaluated for up to 10 years.1​​​​​​​
    • 10 years following Nimenrix vaccination, a proportion of individuals vaccinated at 12-23 months of age and the majority of individuals vaccinated at 2-55 years of age maintained seroprotection (rSBA titres ≥1:8) for serogroups A, C, W and Y.
  • Nimenrix has a well established safety profile evaluated in clinical studies of over 10,000 individuals.1
  • Nimenrix is supplied with the solvent in a pre-filled syringe, powder in a vial and two needles. 1,6
  • ​​​​​​​Nimenrix is certified Halal by the Halal Food Council of Europe. 7

*Note, infants from 6 weeks to less than 6 months of age: two doses, each of 0.5 ml, should be administered with an interval of 2 months between doses. A booster dose should be given at 12 months of age with an interval of at least 2 months after the last Nimenrix vaccination.

See the Nimenrix Summary of Product Characteristics for further details on dosage.

References

Nimenrix. Summary of Product Characteristics, GB, Pfizer Ltd. Available hereTravelHealthPro. Meningococcal Disease fact sheet. Available here (Last accessed September 2023).Travel Health Pro. Hajj and Umrah. Available here  (Last accessed September 2023).The Council of British Hajjis UK (CBHUK). Hajj Debrief calls on the industry to join forces in serving British pilgrims. Available here (Last accessed September 2023). Pulse. Travel Medicine Guide. Available here (Last accessed September 2023).Pfizer Ltd Data on File,Pfizer Ltd Data on File.
PP-NIM-GBR-0401. September 2023
Educational Module Series

Five educational training modules explaining meningococcal disease and who might be at increased risk, types of meningococcal vaccination and the details of Nimenrix vaccine and administration. Each is accompanied by a knowledge check Q&A resource.

Access the resources
Loading
Order Clinic Materials

Help your customers to feel confident about meningococcal disease - access MedISA to order printed clinic support materials to your surgery, pharmacy or other healthcare centre.

 Order materials nowLoading
Register to receive personalised marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

 Sign up hereLoading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​